Degeneration of brain cells is a hallmark symptom of Alzheimer's disease (ad). It's the main cause of dementia, which is typified by a loss of curiosity and autonomy in one's day-to-day life. It has been observed that the only therapies for ADS are symptomatic treatments, but no cure. Alzheimer's disease is a kind of neurodegeneration first identified by Alois Alzheimer in 1906; neurodegenerative diseases are a major challenge for the current health care system. It's a complicated disease with many unknown causes, although neuronal damage, memory problems, and other symptoms are common. The pathological hallmarks of Alzheimer's disease include acetyl cholinergic neuron dysfunction, neurofibrillary tangles, and amyloid- (A) plaque deposition across neurons. Age, genetics, head trauma, AMI, infections, and environmental factors are all potential contributors to the development of this illness. Physical activity and healthy eating have both been linked to decreased risk and protection against the condition. Biomarkers in cerebrospinal fluid, positron emission tomography, computed tomography, magnetic resonance imaging, and electro encephalography are used for prognosis. Drugs including tacrine, donepezil, rivastigmine, galantamine, and N-methyl-D-aspartate glutamate antagonist (NMDA) memantine are currently available as FDA-approved, standard pharmaceutical treatments for Alzheimer's disease (AD). This evaluation discusses presently available drugs and different methods to the diagnosis of AD and varoius mode of treatment of AD.